Atypical femoral fractures

Clinical Cases in Mineral and Bone Metabolism

Volumn 10, Issue 1, 2013, Pages 30-33

  Giannini, Sandro ^a   Chiarello, Eugenio ^a   Tedesco, Giuseppe ^a   Cadossi, Matteo ^a   Luciani, Deianira ^a   Mazzotti, Antonio ^a   Donati, Davide Maria ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atypical femoral fractures; Bisphosphonates; Surgical treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; VITAMIN D;

ATYPICAL FEMUR FRACTURE; BONE BIOPSY; BONE MINERALIZATION; BONE REMODELING; BONE SCINTISCANNING; BONE TURNOVER; CALCIUM BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CROSS LINKING; DISEASE DURATION; ETIOLOGY; FEMUR FRACTURE; FRACTURE TREATMENT; HUMAN; INTRAMEDULLARY NAILING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOSYNTHESIS; RADIODIAGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STRESS FRACTURE; VASCULARIZATION; VITAMIN BLOOD LEVEL;

EID: 84878340368     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: 10.11138/ccmbm/2013.10.1.030     Document Type: Review

References (36)

1. Komadina R. Hip, Osteoporosis: new paradigm. Eur J Trauma Emerg Surg 2008 April;34(2): 163-170.
2. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006 feb;194(2 Suppl):S3-11.
3. Schuiling KD, Robinia K, Nye R. Osteoporosis update. J Midwifery Womens Health 2011 Nov- Dec;56(6): 615-27.
4. Briot K, Cortet B, Thomas T, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 2012 may;79(3): 304-13.
5. Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012 jun;97(6): 1871-80.
6. Cundy T. Recent advances in osteogenesis imperfecta. Calcif Tissue Int 2012 jun;90(6): 439-49.
7. Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012 jul;97(7): 2272-82.
8. Francis RM. Non-response to osteoporosis treatment. J Br Menopause Soc 2004 Jun;10(2): 76-80.
9. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005 Mar;90(3): 1294-301.
10. Kim SY, Schneeweiss S, Katz JN, et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 2011 May;26(5): 993-1001.
11. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010 Dec;95(12): 5258-65.
12. Papapoulos SE. Bisphosphonates: How do they work? Best Pract Res Clin Endocrinol Metab 2008 Oct;22(5): 831-47.
13. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001Nov;69(5): 281-6.
14. Komatsubara S, Mori S, Mashiba T, et al. Suppressed bone turnover by longterm bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004 Jun;19(6): 999-1005.
15. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001May;28(5): 524-31.
16. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010 Nov;25(11): 2267-94.
17. Zioupos P, Currey JD, Hamer AJ. The rule of collagen in the declining mechanism proprieties of aging human cortical bone. J Biomed Mather Res 1999 May;45(2): 108-16.
18. Veashishth D. Advanced glication end product and bone fractures. IBMS BoneKEy 2009;6: 268-278.
19. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increase bone streinght by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000 Nov;27(5): 687-94.
20. Roschger P, Rinnerthaler S, Yates J, et al. Alendronate increase degree and uniformity of mineralization in cancellous bone an decrease the porosity in cortical bone of osteoporotic women. Bone 2001 Aug;29(2): 185-191.
21. Donnelly E, Meredith DS, Nguyen JT, et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 2012 Mar;27(3): 672-8.
22. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002 Sep;302(3): 1055-61.
23. Deckers MM, Van Beek ER, Van Der Pluijm G, et al. Dissotiation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. JBMR 2002 Jun;17(6): 998-1007.
24. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002 Nov 15;62(22): 6538-44.
25. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010 Aug;47(2): 169-80.
26. Mohan PC, Howe TS, Koh JS, Png MA. Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy. Eur Radiol 2013 Jan;23(1): 222-7.
27. Grady MK, Watson JT, Cannada LK. Treatment of femoral fracture nonunion after long-term bisphosphonate use. Orthopedics 2012 Jun;35(6):e991-5.
28. Weill YA, Rivkin G, Safran O, The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 2011 Jul;71(1): 186-90.
29. Fowler JR, Criner K, Craig MR. Prophylactic intramedullary fixation for bisphosphonate- related subtrochanteric stress fracture. Orthopedics 2012 Jun;35(6):e954-7.
30. Carvalho NN, Voss LA, Almeida MO, et al. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab 2011 Sep;96(9): 2675-80.
31. Banffy MB, Vrahas MS, Ready JE. Nonoperative versus prophylactic treatment of bisphosphonate- associated femoral stress fractures. Clin Orthop Relat Res 2011 Jul;469(7): 2028-34.
32. Ha YC, Cho MR, Park KH, et al. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res 2010 Dec;468(12): 3393-8.
33. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009 Jun;24(6): 1095-102.
34. European Medicines Agency concludes class review of bisphosphonates and atypical fractures, EMA/CHMP/292784/2011, 2011 Apr.
35. Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 2010 Mar;8(1): 34-9.
36. Gunawardena I, Baxter M, Rasekh Y. Bisphosphonate-Related Subtrochanteric Femoral Fractures. Am J Geriatr Pharmacother 2011 Jun;9(3): 194-8.